| Hologic to Webcast Presentations at Upcoming Investor Conferences |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentations at Upcoming Investor Conferences. |
businesswire.com |
2025-05-13 20:10:00 |
Czytaj oryginał (ang.) |
| Understanding Hologic (HOLX) Reliance on International Revenue |
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. |
zacks.com |
2025-05-13 14:22:27 |
Czytaj oryginał (ang.) |
| Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock? |
Women's health device maker, Hologic HOLX, slashed its earnings forecast for the full fiscal 2025, even as the latest second-quarter results topped expectations. The revenue target of $4.05-$4.10 billion remained the same as stated during the February earnings call, reflecting the $100 million cut from the initial guidance. |
zacks.com |
2025-05-12 13:46:06 |
Czytaj oryginał (ang.) |
| Hologic: Soft Performance, But Cheap Enough |
Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage. |
seekingalpha.com |
2025-05-06 21:39:53 |
Czytaj oryginał (ang.) |
| Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know |
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-05-06 14:05:56 |
Czytaj oryginał (ang.) |
| Hologic Q2 Earnings & Revenues Top, '25 EPS View Lowered, Stock Down |
HOLX delivers earnings and revenue beat in the second quarter of fiscal 2025 amid macroeconomic turbulence. |
zacks.com |
2025-05-02 12:25:33 |
Czytaj oryginał (ang.) |
| Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript |
Hologic, Inc. (NASDAQ:HOLX ) Q2 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Mike Watts - Corporate VP, IR Steve MacMillan - Chairman, President & CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Anthony Petrone - Mizuho Group Lu Li - UBS Casey Woodring - JP Morgan Conor McNamara - RBC Capital Andrew Cooper - Raymond James Mason Carrico - Stephens Operator Good afternoon, and welcome to Hologic's Second Quarter Fiscal 2025 Earnings Conference Call. My name is Rachel, and I'm your operator for today's call. |
seekingalpha.com |
2025-05-02 00:24:47 |
Czytaj oryginał (ang.) |
| Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty |
Medical equipment maker Hologic lowered its fiscal 2025 profit forecast, citing uncertainty around the tariffs imposed by U.S. President Donald Trump's administration, sending the company's shares down 3% after the bell on Thursday. |
reuters.com |
2025-05-01 22:58:33 |
Czytaj oryginał (ang.) |
| Hologic (HOLX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates |
While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-01 22:30:33 |
Czytaj oryginał (ang.) |
| Hologic (HOLX) Tops Q2 Earnings and Revenue Estimates |
Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.03 per share a year ago. |
zacks.com |
2025-05-01 22:10:20 |
Czytaj oryginał (ang.) |
| Hologic Announces Financial Results for Second Quarter of Fiscal 2025 |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for Second Quarter of Fiscal 2025. |
businesswire.com |
2025-05-01 20:01:00 |
Czytaj oryginał (ang.) |
| Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss? |
The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar. |
zacks.com |
2025-04-30 14:35:40 |
Czytaj oryginał (ang.) |
| Insights Into Hologic (HOLX) Q2: Wall Street Projections for Key Metrics |
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-04-28 14:22:04 |
Czytaj oryginał (ang.) |
| GYN Surgical Division Likely to Drive Hologic's Q2 Earnings |
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings. |
zacks.com |
2025-04-28 13:45:37 |
Czytaj oryginał (ang.) |
| Hologic Set to Report Q2 Earnings: Buy, Sell or Hold the Stock? |
Molecular Diagnostics is likely to have aided HOLX's performance in the second quarter of fiscal 2025. |
zacks.com |
2025-04-25 13:20:36 |
Czytaj oryginał (ang.) |
| Cellulite Treatment Market Trends, Growth Opportunities and Shares 2025-2030; Featuring Key Players - Hologic (Cynosure), Merz Pharma, Syneron Medical, Zimmer Aesthetics & More |
Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Cellulite Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering. The Global Cellulite Treatment Market was valued at USD 1.57 billion in 2024 and is expected to reach USD 2.47 billion by 2030 with a CAGR of 7.84% during the forecast period. The global cellulite treatment market is a dynamic and rapidly growing segment within the broader healthcare and wellness industry. |
globenewswire.com |
2025-04-25 08:25:00 |
Czytaj oryginał (ang.) |
| Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI. |
businesswire.com |
2025-04-24 12:10:00 |
Czytaj oryginał (ang.) |
| Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It |
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2025-04-23 14:06:11 |
Czytaj oryginał (ang.) |
| Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside? |
In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market. According to Roots Analysis, the IVD market is projected to witness a 6.2% compound annual growth rate through 2035. |
zacks.com |
2025-04-22 15:10:42 |
Czytaj oryginał (ang.) |
| Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report. |
businesswire.com |
2025-04-22 12:08:00 |
Czytaj oryginał (ang.) |
| Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock? |
HOLX's latest regulatory successes draw investors' attention. However, macroeconomic challenges restrict its full growth potential. |
zacks.com |
2025-02-26 11:05:38 |
Czytaj oryginał (ang.) |
| Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference. |
businesswire.com |
2025-02-25 10:15:00 |
Czytaj oryginał (ang.) |
| Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know |
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-02-24 12:05:39 |
Czytaj oryginał (ang.) |
| Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #cemark--Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software. |
businesswire.com |
2025-02-20 05:00:00 |
Czytaj oryginał (ang.) |
| Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #aptima--Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay. |
businesswire.com |
2025-02-18 10:08:00 |
Czytaj oryginał (ang.) |
| Two S&P 500 hidden gems to buy right now |
Although the benchmark S&P 500's biggest names tend to dominate investor attention, the index also features lesser-known stocks with significant growth potential. |
finbold.com |
2025-02-18 07:49:05 |
Czytaj oryginał (ang.) |
| HOLX's New Offerings Likely to Revive Stock Amid Macro Woes |
Hologic's Surgical business has been recording strong broad-based performance by expanding access to technologies into new global markets. |
zacks.com |
2025-02-13 13:57:10 |
Czytaj oryginał (ang.) |
| Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™. |
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg |
https://www.prnewswire.com |
2025-02-13 12:05:00 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain HOLX Stock in Your Portfolio Now |
Hologic's strength in the molecular diagnostics wing instills optimism among investors. Yet, a dull macroeconomic environment raises concerns. |
zacks.com |
2025-02-13 10:56:12 |
Czytaj oryginał (ang.) |
| Deciphering Hologic (HOLX) International Revenue Trends |
Examine the evolution of Hologic's (HOLX) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects. |
zacks.com |
2025-02-11 12:16:22 |
Czytaj oryginał (ang.) |
| Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It |
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2025-02-11 12:05:30 |
Czytaj oryginał (ang.) |
| Here's Why Hologic (HOLX) is a Strong Momentum Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-02-06 12:51:13 |
Czytaj oryginał (ang.) |
| Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance |
HOLX's fiscal 2025 first-quarter results reflect the strength of its Molecular Diagnostics business. |
zacks.com |
2025-02-06 10:26:16 |
Czytaj oryginał (ang.) |
| Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript |
Hologic, Inc. (NASDAQ:HOLX ) Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Mike Watts - Corporate Vice President, IR Steve MacMillan - Chairman, President and CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Anthony Petrone - Mizuho Group Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Tycho Peterson - Jefferies Casey Woodring - JP Morgan Tejas Savant - Morgan Stanley Ryan Zimmerman - BTIG Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Andrew Cooper - Raymond James Operator Good afternoon. And welcome to the Hologic's First Quarter Fiscal 2025 Earnings Conference Call. |
seekingalpha.com |
2025-02-06 00:06:03 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Hologic (HOLX) Q1 Earnings: A Look at Key Metrics |
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-05 20:30:35 |
Czytaj oryginał (ang.) |
| Hologic (HOLX) Q1 Earnings Surpass Estimates |
Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.98 per share a year ago. |
zacks.com |
2025-02-05 20:16:12 |
Czytaj oryginał (ang.) |
| Hologic cuts annual revenue forecast on weak demand for breast health products |
Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company's shares down 5% after the bell on Wednesday. |
reuters.com |
2025-02-05 19:56:33 |
Czytaj oryginał (ang.) |
| Hologic Announces Financial Results for First Quarter of Fiscal 2025 |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for First Quarter of Fiscal 2025. |
businesswire.com |
2025-02-05 18:01:00 |
Czytaj oryginał (ang.) |
| Can These 5 MedTech Stocks Hit Earnings Targets This Season? |
Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow. |
zacks.com |
2025-02-04 14:10:43 |
Czytaj oryginał (ang.) |
| Hologic (HOLX) is a Top-Ranked Value Stock: Should You Buy? |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-02-04 12:40:58 |
Czytaj oryginał (ang.) |
| Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz |
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year |
youtube.com |
2025-01-03 14:06:01 |
Czytaj oryginał (ang.) |
| Hologic (HOLX) Falls More Steeply Than Broader Market: What Investors Need to Know |
Hologic (HOLX) concluded the recent trading session at $71.74, signifying a -0.49% move from its prior day's close. |
zacks.com |
2025-01-02 21:16:43 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain HOLX Stock in Your Portfolio Now |
Hologic's strength in the Surgical wing instills optimism among investors. Yet, currency impacts raise concerns. |
zacks.com |
2025-01-02 09:41:24 |
Czytaj oryginał (ang.) |
| Hologic (HOLX) Flat As Market Sinks: What You Should Know |
Hologic (HOLX) closed at $72.68 in the latest trading session, marking no change from the prior day. |
zacks.com |
2024-12-26 20:51:29 |
Czytaj oryginał (ang.) |
| Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know |
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2024-12-24 12:01:32 |
Czytaj oryginał (ang.) |
| Hologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain? |
Via an agreement with the CDC, Hologic is set to develop ASRs for launching the H5N1 bird flu test. |
zacks.com |
2024-12-24 10:21:12 |
Czytaj oryginał (ang.) |
| Here's Why Hologic (HOLX) Fell More Than Broader Market |
Hologic (HOLX) closed the most recent trading day at $70.76, moving -0.99% from the previous trading session. |
zacks.com |
2024-12-19 20:51:30 |
Czytaj oryginał (ang.) |
| Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #H5N1--Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC. |
businesswire.com |
2024-12-18 10:08:00 |
Czytaj oryginał (ang.) |
| Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It |
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2024-12-13 12:01:21 |
Czytaj oryginał (ang.) |
| Hologic Trades at 17.62X P/E: Should You Buy, Sell or Hold the Stock? |
Despite the current challenges, HOLX's portfolio strength and international growth prospects make it worth holding on to. |
zacks.com |
2024-12-11 10:55:34 |
Czytaj oryginał (ang.) |
| Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #USPSTF--Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines. |
businesswire.com |
2024-12-10 18:01:00 |
Czytaj oryginał (ang.) |
| Martin Madaus Elected to Hologic Board of Directors |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #boardofdirectors--Martin Madaus Elected to Hologic Board of Directors. |
businesswire.com |
2024-12-09 18:05:00 |
Czytaj oryginał (ang.) |
| New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--New Data To Be Presented at SABCS 2024 Investigates the Potential Role of Breast Cancer IndexTest. |
businesswire.com |
2024-12-09 10:05:00 |
Czytaj oryginał (ang.) |
| HOLX Stock Set to Gain From New Study Data on Genius AI Detection 2.0 |
Hologic upholds its focus on equity with new research findings on its Breast Imaging AI solution. |
zacks.com |
2024-12-03 10:01:17 |
Czytaj oryginał (ang.) |
| Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know |
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2024-12-02 16:30:45 |
Czytaj oryginał (ang.) |
| Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations. |
businesswire.com |
2024-12-02 10:08:00 |
Czytaj oryginał (ang.) |
| Hologic to Debut AI-Powered Innovations at RSNA 2024: Stock to Gain? |
HOLX will unveil breakthrough innovations at this year's RSNA, focusing on imaging solutions and AI. |
zacks.com |
2024-11-28 10:15:23 |
Czytaj oryginał (ang.) |
| Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024 |
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #3Dmammogram--Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024. |
businesswire.com |
2024-11-25 10:22:00 |
Czytaj oryginał (ang.) |
| Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know |
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2024-11-19 12:06:26 |
Czytaj oryginał (ang.) |
| Should You Retain Hologic Stock in Your Portfolio Now? |
HOLX's strength in the Molecular Diagnostics wing instills optimism among investors. Yet, macro woes and currency impacts raise concerns. |
zacks.com |
2024-11-15 09:41:09 |
Czytaj oryginał (ang.) |